18 Share Tips | 26th August 2024 | The BullBUY – Botanix Pharmaceuticals (BOT)
The US Food and Drug Administration (FDA) has approved BOT’s Sofdra topical gel, a prescription medicine for treating primary axillary hyperhidrosis (excessive underarm sweating) in adults and children aged 9 and beyond. The product is already marketed in Japan, but the US potentially provides a much bigger opportunity. BOT, a clinical dermatology company, says about 10 million in the US suffer from excessive underarm sweating. FDA approval paints a brighter revenue outlook.
Updated today..
BOT - Anything but charting, page-9877
-
- There are more pages in this discussion • 999 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.010(2.63%) |
Mkt cap ! $671.1M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 37.0¢ | $1.949M | 5.207M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 163455 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 33207 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| BOT (ASX) Chart |